GRAIL, LLC (GRAL)vsIQVIA Holdings Inc (IQV)
GRAL
GRAIL, LLC
$69.48
+9.59%
HEALTHCARE · Cap: $2.94B
IQV
IQVIA Holdings Inc
$238.70
+2.70%
HEALTHCARE · Cap: $38.68B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 10778% more annual revenue ($16.98B vs $156.12M). IQV leads profitability with a 8.1% profit margin vs -253.2%. IQV earns a higher WallStSmart Score of 55/100 (C).
GRAL
Hold35
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GRAL.
Margin of Safety
+11.9%
Fair Value
$201.09
Current Price
$238.70
$37.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 28.1% year-over-year
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
ROE of -15.8% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Moderate valuation
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GRAL
The strongest argument for GRAL centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 28.1% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
GRAL profiles as a growth stock while IQV is a value play — different risk/reward profiles.
GRAL carries more volatility with a beta of 3.22 — expect wider price swings.
GRAL is growing revenue faster at 28.1% — sustainability is the question.
IQV generates stronger free cash flow (491M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.
Visit Website →IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?